Clinic Software← All companies
Evercrisp Biosciences
Redefining what is possible in genetic medicine
health AI / medtech / digital health (genetic medicines delivery)
StageSeries A
Raised$3.5M
Founded2021
Employees5
LocationBerkeley, CA
Business modelB2B / B2B2C (enterprise biotech partnerships and collaborations)
About
Evercrisp Biosciences is innovating at the molecular level to enable precise, safe, and scalable delivery of genetic therapies into target tissues. Evercrisp applies proprietary technologies from world-renowned scientific founders to design miniproteins that can access brain, kidney, muscle, and other tissues previously unreachable by genetic medicines. Evercrisp miniproteins are “self-delivering” – they do not require assisted delivery via LNPs, viral vectors, or other vehicles that can trigger immune responses.
Product
- Value proposition
- Platform of machine learning–engineered miniproteins for receptor-mediated delivery of genetic therapies to previously inaccessible tissues, enabling safer, systemic, repeatable dosing and broader therapeutic reach.
Founders
- Jennifer Doudna
- Tanja Kortemme
- Spiros Liras
Categories
Products
Evercrisp miniproteins platformSelf-delivering miniproteins with endosomal escape elements (for receptor-mediated delivery)
Key features
Self-delivering miniproteinsEndosomal escape technologyReceptor-mediated delivery of ASOs and siRNAsSystemic, tissue-targeted delivery without viral vectors or LNPsScalable manufacturingMachine learning–engineered proteins
Technologies
Miniprotein designMachine learningEndosomal escapeOligonucleotide delivery (ASOs, siRNAs)Protein engineering
Certifications
FDA status:nullSOC 2:nullCLIA:nullHITRUST:null
Partnerships
Collaborations with leading scientists (Jennifer Doudna, Tanja Kortemme) and research-based partnerships mentioned; external partnerships not specified
Traction metrics
Global reach: scalable manufacturing for worldwide accessibility
Investors
Apple Tree Partners (ATP)University of California, Berkeley
News
- Evercrisp Biosciences · 2025-01-24T00:00:00.000Z
- California-Based Biotech Company Files Chapter 11 Bankruptcy · 2026-01-02T16:32:37.000Z
- Apple Tree says its biotechs face 'imminent collapse' - Endpoints News · 2025-07-05T00:00:00.000Z
- Amplified genome editing by in vivo editor production | bioRxiv · 2026-01-01T14:41:22.000Z
- Epicrispr banks $68M to test epigenetic editing on rare muscle disease | BioPharma Dive · 2025-03-26T08:00:00.000Z
- Epicrispr Biotechnologies to Begin Clinical Trials for its Lead Epigenetic Therapy for FSHD Patients · 2025-03-27T10:31:36.000Z
